|1.||Oelschlaeger, Tobias A: 5 articles (10/2014 - 06/2005)|
|2.||Schulze, J: 4 articles (09/2008 - 05/2004)|
|3.||Howarth, Gordon S: 3 articles (01/2015 - 04/2011)|
|4.||Sonnenborn, Ulrich: 3 articles (10/2014 - 03/2007)|
|5.||Petersen, Andreas Munk: 2 articles (12/2015 - 11/2014)|
|6.||Wang, Hanru: 2 articles (01/2015 - 05/2014)|
|7.||Lawrence, Andrew: 2 articles (01/2015 - 05/2014)|
|8.||Bastian, Susan E P: 2 articles (01/2015 - 05/2014)|
|9.||Tedin, Karsten: 2 articles (05/2014 - 01/2011)|
|10.||Schierack, Peter: 2 articles (05/2014 - 01/2011)|
09/01/2008 - "Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study."
03/01/2014 - "The probiotic Escherichia coli Nissle 1917 (EcN) is widely used to maintain remission in ulcerative colitis. "
01/01/2014 - "Most studies about EcN has been devoted to this organism efficacy in ulcerative colitis treatment. "
12/01/2015 - "Escherichia coli Nissle 1917 (EcN) has been recommended as a therapeutic tool for ulcerative colitis (UC) treatment. "
02/01/2010 - "coli Nissle 1917 (EcN) are both effective agents for the treatment of ulcerative colitis. "
10/01/2014 - "Oral EcN administration after TNBS-induced improved colitis dose dependently. "
10/01/2014 - "This study convincingly demonstrates that pre-administration of probiotic EcN with low dose is able to protect colitis of rats and mediate up-regulation of ZO-1 expression, but long-term of high-dose EcN may do harm to colitis."
10/01/2014 - "To analyze the in vivo effect of Escherichia coli Nissle 1917 (EcN) with different courses and different doses to Sprague-Dawley rats with trinitrobenzene sulfonic acid (TNBS)-induced colitis. "
12/01/2009 - "Probiotic bacteria Escherichia coli Nissle (EcN) was shown to prevent or heal acute murine colitis, but gastroprotective effects of EcN against mucosal injury have been little studied. "
03/01/2004 - "In this model, preexisting colitis was necessary for translocation of EcN and resident E. "
06/01/2008 - "In the conditions of this trial EcN was a suitable remedy for diarrhea >4 days in young children."
06/01/2008 - "The efficacy of probiotic Escherichia coli Nissle 1917 (EcN) in infants and toddlers with diarrhea >4 days was tested by a double-blind trial. "
01/01/2014 - "In studies conducted among children a positive impact of EcN in prevention and treatment of diarrhea was demonstrated. "
01/01/2015 - "Here, we investigated its effect on the growth of diarrhea-reducing probiotic Lactobacillus rhamnosus GG (LGG) and Escherichia coli Nissle (EcN), and the resulting effects on HRV diarrhea, gut epithelial health, permeability and innate immune responses during virulent HRV challenge. "
06/01/2008 - "One hundred fifty-one children aged 1-47 months with nonspecific diarrhea were randomized to receive either EcN suspension (N = 75) or placebo (N = 76). "
04/01/2006 - "This infection model with freshly weaned piglets may be predestinated to further characterize EcN effects on the cellular level, i.e., involved second messenger pathways, or it may also be useful to examine the efficacy of other substrates or microbe strains against secretory stimuli."
05/01/2014 - "In this study, we examined the inhibitory effect of EcN on infections of porcine intestinal epithelial cells with atypical enteropathogenic E. "
05/01/2014 - "We show that EcN drastically reduced the infection efficiencies of aEPEC by inhibiting bacterial adhesion and growth of microcolonies, but not the attaching and effacing of adherent bacteria. "
04/01/2011 - "In this report, we investigate the potential of the probiotic Escherichia coli Nissle 1917 (EcN) to reduce features associated with AIEC pathogenicity in an already established infection with AIEC reference strain LF82."
02/01/2011 - "The colonization, translocation and protective effect of two intestinal bacteria - PR4 (pig commensal strain of Bifidobacterium choerinum) or EcN (probiotic Escherichia coli strain Nissle 1917) - against subsequent infection with a virulent LT2 strain of Salmonella enterica serovar Typhimurium were studied in gnotobiotic pigs after oral association. "
|5.||Crohn Disease (Crohn's Disease)
11/01/2012 - "In contrast to ulcerative colitis, for Crohn's disease (CD) convincing evidence is lacking that EcN might be clinically effective, most likely due to the genetically based inability of sufficient defensin production in CD patients. "
01/01/2014 - "The use of EcN in Crohn's disease has not been the subject of as many studies as in the case of ulcerative colitis. "
06/04/2013 - "In the treatment of ulcerative colitis and Crohn's disease, the recombinant strain of EcN can be used as a target therapeutics for defensins presenting. "
|7.||PQQ Cofactor (Pyrroloquinoline Quinone)
|5.||Drug Therapy (Chemotherapy)